ezetimibe has been researched along with lovastatin in 30 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (lovastatin) | Trials (lovastatin) | Recent Studies (post-2010) (lovastatin) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 4,828 | 698 | 873 |
| Protein | Taxonomy | ezetimibe (IC50) | lovastatin (IC50) |
|---|---|---|---|
| Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | 2.4 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0261 | |
| Integrin beta-2 | Homo sapiens (human) | 3.09 | |
| Intercellular adhesion molecule 1 | Homo sapiens (human) | 3.78 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 8.753 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 10 | |
| Neutrophil elastase | Homo sapiens (human) | 0.027 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.02 | |
| Integrin alpha-L | Homo sapiens (human) | 3.09 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 8.753 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.02 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0529 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 15 (50.00) | 29.6817 |
| 2010's | 14 (46.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afonso, A; Burnett, DA; Clader, JW; Davis, HR; Huynh, T; Rosenblum, SB; Yumibe, N | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW | 1 |
| Corbelli, J; Kerzner, B; LeBeaut, A; Lipka, LJ; Melani, L; Mukhopadhyay, P; Sharp, S; Suresh, R; Veltri, EP | 1 |
| Tellier, P | 1 |
| Cutler, DL; Kosoglou, T; Maxwell, SE; Meyer, I; Musiol, B; Statkevich, P; Veltri, EP; Yang, B; Zhu, Y | 1 |
| Boutros, T; Kosoglou, T; Reyderman, L; Seiberling, M; Statkevich, P | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Bennett, S; Lipka, L; Melani, L; Sager, P; Suresh, R; Veltri, E | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Hegele, RA; Liu, DM; Miskie, BA; Tadiboyina, VT; Wang, J | 1 |
| Bennett, MK; Datta, S; Osborne, TF; Seo, YK; Shin, DJ | 1 |
| Hanson, M; Hoffman, R; Strony, J; Veltri, E | 1 |
| Chen, CW; Hsueh, CH; Hwang, JJ; Lai, LP; Shen, MJ; Su, YN; Tsai, CT | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Charland, SL; Malone, DC | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Arca, M; Budal, S; Degli Esposti, E; Degli Esposti, L; Sangiorgi, D; Vigna, GB | 1 |
| Biddinger, SB; Haas, JT; Kurland, IJ; Manthena, P; Miao, J; Vaitheesvaran, B; Wang, Y; Zhao, E | 1 |
| Appeltans, B; Engelen, A; Riekes, MK; Rombaut, P; Stulzer, HK; Van den Mooter, G | 1 |
| Ahn, SC; Jang, HJ; Jeon, TI; Kim, KY; Osborne, TF; Park, KI; Seo, J; Seo, YK; Shin, IW; Suh, PG; Yang, YR | 1 |
| Augustijns, P; Berben, P; Dereymaker, A; Riekes, MK; Stulzer, HK; Van den Mooter, G | 1 |
| Di Giacomo, S; Mazza, F; Mesce, D; Morozzi, C; Pergolini, M; Stefanutti, C; Vitale, M | 1 |
| Blanchard, V; Blom, DJ; Bourane, S; Cariou, B; Chemello, K; Croyal, M; Farnier, M; Lambert, G; Nativel, B; Pichelin, M; Raal, FJ; Ramin-Mangata, S; Tang, L; Thedrez, A | 1 |
| Gaviria-Mendoza, A; Machado-Alba, JE; Machado-Duque, ME | 1 |
3 review(s) available for ezetimibe and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
6 trial(s) available for ezetimibe and lovastatin
| Article | Year |
|---|---|
Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hypercholesterolemia; Lipoprotein(a); Lovastatin; Male; Middle Aged; Practice Guidelines as Topic; Safety; Treatment Outcome; Triglycerides | 2003 |
Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Lovastatin; Male; Placebos; Reference Values; Single-Blind Method; United States | 2004 |
Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Reference Values | 2004 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Arthralgia; Azetidines; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Headache; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Patient Dropouts; Pravastatin; Respiratory Tract Infections; Simvastatin; Sinusitis; Treatment Outcome; Triglycerides | 2008 |
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoprotein B-100; Cells, Cultured; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Middle Aged; Mutation; PCSK9 Inhibitors; Phenotype; Receptors, LDL; Serine Proteinase Inhibitors; Treatment Outcome; Young Adult | 2018 |
21 other study(ies) available for ezetimibe and lovastatin
| Article | Year |
|---|---|
Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cricetinae; Drug Design; Ezetimibe; Liver; Structure-Activity Relationship | 1998 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, Dietary; Dogs; Drug Combinations; Drug Synergism; Ezetimibe; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Lovastatin; Male; Pravastatin; Simvastatin; Time Factors | 2001 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Intestinal Absorption; Lovastatin; Muscular Diseases; Niacin | 2003 |
Three new drugs for hyperlipidemia.
Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Niacin | 2003 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sex Factors; Simvastatin; Time Factors; Treatment Outcome; Women's Health | 2004 |
Treatment of dyslipidemia with lovastatin and ezetimibe in an adolescent with cholesterol ester storage disease.
Topics: Adolescent; Amino Acid Sequence; Azetidines; Base Sequence; Child; Child, Preschool; Cholesterol Ester Storage Disease; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins; Lovastatin; Male; Molecular Sequence Data; Sterol Esterase | 2005 |
Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver.
Topics: Animals; Anticholesteremic Agents; Azetidines; Dietary Supplements; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fasting; Fatty Acid Synthases; Gene Expression Regulation, Enzymologic; Homeostasis; Hydroxymethylglutaryl CoA Reductases; Lipid Metabolism; Liver; Lovastatin; Male; Mice; Response Elements; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Sterol Regulatory Element Binding Protein 2 | 2008 |
The g.-762T>C polymorphism of the NPC1L1 gene is common in Chinese and contributes to a higher promoter activity and higher serum cholesterol levels.
Topics: Asian People; Azetidines; China; Cholesterol; Demography; Ezetimibe; Female; Gene Frequency; Genotype; Hep G2 Cells; Humans; Hypercholesterolemia; Lovastatin; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Polymorphism, Single Nucleotide; Promoter Regions, Genetic | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
[Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
Topics: Aged; Algorithms; Azetidines; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Lovastatin; Male; Medication Adherence; Middle Aged; Pravastatin; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins.
Topics: Animals; Azetidines; Biosynthetic Pathways; Cholesterol; Ezetimibe; Fasting; Gene Expression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipogenesis; Liver; Lovastatin; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Receptor, Insulin; Sterol Regulatory Element Binding Protein 2; Transcriptional Activation; Transcriptome | 2014 |
New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.
Topics: Anticholesteremic Agents; Calorimetry, Differential Scanning; Crystallization; Desiccation; Drug Combinations; Drug Compounding; Drug Stability; Ezetimibe; Lovastatin; Water; X-Ray Diffraction | 2016 |
SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy.
Topics: Animals; Anticholesteremic Agents; Autophagosomes; Autophagy; Cells, Cultured; Diet, High-Fat; Disease Models, Animal; Drug Therapy, Combination; Ezetimibe; Group VI Phospholipases A2; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Triglycerides | 2016 |
Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters.
Topics: Acrylic Resins; Delayed-Action Preparations; Drug Combinations; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; Ezetimibe; Hydrogen-Ion Concentration; Lovastatin; Polyethylene Glycols; Polymethacrylic Acids; Polyvinyls | 2017 |
Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: A clinical study.
Topics: Adult; Aged; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Diet, Fat-Restricted; Dietary Supplements; Ezetimibe; Female; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Monascus; Mutation; Phenotype; Time Factors; Treatment Outcome; Young Adult | 2017 |
Lipid-lowering drug prescriptions in a group of Colombian patients.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Atorvastatin; Cities; Colombia; Cross-Sectional Studies; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Sex Distribution; Young Adult | 2019 |